Merck KGaA has tapped nascent artificial intelligence developer Quris for its digital drug safety prediction platform, which includes experiments run on miniaturized human tissues encased on small chips built from stem cells.

More than a year after submitting its application to the FDA—and many months later than Senseonics expected to receive the agency’s sign-off—the diabetes technology developer has finally scored approval for its implanted continuous glucose monitor designed for long-term use.

In a rare moment of solidarity among fierce competitors, Biogen’s peers Roche and Eli Lilly are rallying behind the company’s troubled Alzheimer’s disease therapy, Aduhelm, in an effort to change the Centers for Medicare & Medicaid Services’(CMS’) restrictive ruling against monoclonal antibodies for the condition.

How does a medtech company top its “best year ever”? According to Dexcom, by adding another half-billion dollars in revenue, growing the customer base by upwards of 30% and collecting a handful of regulatory clearances for new product launches.

Cassava Sciences has chalked up one win in an ongoing battle over the integrity of its clinical trials for Alzheimer’s disease. The FDA is declining to intervene in a citizen petition’s plea to halt ongoing clinical trials of the company’s drug, simufilam, saying the petition was not the appropriate venue for such a complaint.

A recent analysis showing that antibiotic-resistant infections were responsible for at least 1.2 million deaths around the world in 2019—a number that could actually reach as high as 5 million and far outstrips other widespread infectious diseases like HIV/AIDS and malaria.

Despite record revenue and continued demand for its DNA sequencers and consumables, Illumina’s net income for 2021’s fourth quarter dropped to $112 million—down 56% compared to the same period the year before—following bigger spends on R&D and administrative expenses.

Curevo Vaccine is hoping $60 million in financing will help the small biotech literally go head-to-head against GlaxoSmithKline’s market-dominating shingles vaccine Shingrix.

It doesn’t take an artificial intelligence-powered symptom checker to diagnose Ada Health with what is clearly a serious case of fundraising fever.

Three years down, many more to go.